1815 A double blind phase 3 trial of fulvestrant with placebo or palbociclib in pre- and post-menopausal women with hormone receptor-positive (HR+ve), HER2-negative (HER2-ve) metastatic breast cancer (MBC) that progressed on prior endocrine therapy (PALOMA 3): Detailed analysis of patient-reported outcomes

Patient Reported Outcomes ◽

Metastatic Breast ◽

Phase 3 ◽

Double Blind ◽

Menopausal Women ◽

Patient Reported ◽

Abstract OT3-2-10: Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of fulvestrant with or without PD-0332991 (palbociclib) ± goserelin in women with hormone receptor-positive, HER2-negative metastatic breast cancer (MBC) whose disease progressed after prior endocrine therapy

10.1158/0008-5472.sabcs13-ot3-2-10 ◽

2013 ◽

Cited By ~ 2

Author(s):

N Turner ◽

F André ◽

S Loibl ◽

J Ro ◽

H Iwata ◽

...

Keyword(s):

Breast Cancer ◽

Endocrine Therapy ◽

Hormone Receptor ◽

Controlled Trial ◽

Metastatic Breast ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Hormone Receptor Positive

Abstract P4-13-03: Updated safety from a double-blind phase 3 trial (PALOMA-3) of fulvestrant with placebo or with palbociclib in pre- and postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy

10.1158/1538-7445.sabcs15-p4-13-03 ◽

2016 ◽

Cited By ~ 1

Author(s):

S Verma ◽

AM DeMichele ◽

S Loi ◽

J Ro ◽

M Colleoni ◽

...

Keyword(s):

Breast Cancer ◽

Postmenopausal Women ◽

Endocrine Therapy ◽

Hormone Receptor ◽

Metastatic Breast ◽

Phase 3 ◽

Double Blind ◽

Hormone Receptor Positive

PCN246 BUDGET IMPACT OF RIBOCICLIB PLUS LETROZOLE FOR THE TREATMENT OF POST-MENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE (HR+), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2- NEGATIVE (HER2-) ADVANCED OR METASTATIC BREAST CANCER IN DENMARK

Value in Health ◽

10.1016/j.jval.2019.09.441 ◽

2019 ◽

Vol 22 ◽

pp. S483

Author(s):

A.H. Møller ◽

L. Oddershede

Keyword(s):

Breast Cancer ◽

Epidermal Growth Factor Receptor ◽

Budget Impact ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Menopausal Women ◽

Epidermal Growth ◽

481 An indirect comparison of aromatase inhibitors (AIs) in the first line treatment of post menopausal women with hormone receptor positive (HR+) metastatic breast cancer (MBC)

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(10)70502-4 ◽

2010 ◽

Vol 8 (3) ◽

pp. 200

Author(s):

J. Kleijnen ◽

R. Riemsma ◽

M.M. Amonkar ◽

K. Lykopoulos ◽

J.R. Diaz ◽

...

Keyword(s):

Breast Cancer ◽

Indirect Comparison ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Menopausal Women ◽

Post Menopausal ◽

First Line Treatment

Predictors of systemic therapy sequences following a CDK 4/6 inhibitor-based regimen in post-menopausal women with hormone receptor positive, HEGFR-2 negative metastatic breast cancer

Current Medical Research and Opinion ◽

10.1080/03007995.2018.1519500 ◽

2018 ◽

Vol 35 (1) ◽

pp. 73-80 ◽

Cited By ~ 4

Author(s):

Nicole Princic ◽

Ayal Aizer ◽

Derek H. Tang ◽

David M. Smith ◽

William Johnson ◽

...

Keyword(s):

Breast Cancer ◽

Systemic Therapy ◽

Hormone Receptor ◽

Metastatic Breast ◽

Menopausal Women ◽

Faculty Opinions recommendation of Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726198033.793559052 ◽

2019 ◽

Author(s):

Ahmad Awada

Keyword(s):

Breast Cancer ◽

Randomised Controlled Trial ◽

Controlled Trial ◽

Metastatic Breast ◽

Final Analysis ◽

Phase 3 ◽

Double Blind ◽

Randomised Controlled

Abstract S1-02: PrECOG 0102: A randomized, double-blind, phase II trial of fulvestrant plus everolimus or placebo in post-menopausal women with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer (MBC) resistant to aromatase inhibitor (AI) therapy

10.1158/1538-7445.sabcs16-s1-02 ◽

2017 ◽

Cited By ~ 14

Author(s):

NS Kornblum ◽

J Manola ◽

P Klein ◽

B Ramaswamy ◽

A Brufsky ◽

...

Keyword(s):

Breast Cancer ◽

Aromatase Inhibitor ◽

Phase Ii ◽

Hormone Receptor ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Double Blind ◽

Menopausal Women ◽

Healthcare medical costs among post-menopausal women with hormone receptor positive and human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer (mBC) managed with systemic therapy following CDK 4/6 inhibitor (CDKi) in the real-world setting.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.1067 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 1067-1067

Author(s):

Nicole Princic ◽

Derek Tang ◽

Aditya Bardia ◽

David Smith ◽

William M. Johnson ◽

...

Keyword(s):

Breast Cancer ◽

Epidermal Growth Factor Receptor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Real World Setting ◽

Menopausal Women ◽

Epidermal Growth ◽

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

The Lancet Oncology ◽

10.1016/s1470-2045(15)00613-0 ◽

2016 ◽

Vol 17 (4) ◽

pp. 425-439 ◽

Cited By ~ 646

Author(s):

Massimo Cristofanilli ◽

Nicholas C Turner ◽

Igor Bondarenko ◽

Jungsil Ro ◽

Seock-Ah Im ◽

...

Keyword(s):

Breast Cancer ◽

Randomised Controlled Trial ◽

Controlled Trial ◽

Metastatic Breast ◽

Final Analysis ◽

Phase 3 ◽

Double Blind ◽

Randomised Controlled

Patient-reported outcomes of palbociclib plus exemestane with GnRH agonist versus capecitabine in premenopausal women with hormone receptor-positive metastatic breast cancer from the YoungPearl phase ll trial (KCSG-BR 15-10, NCT02592746)

Annals of Oncology ◽

10.1093/annonc/mdz394.013 ◽

2019 ◽

Vol 30 ◽

pp. v862

Author(s):

S. Lee ◽

Y.H. Park ◽

S.-A. Im ◽

K.H. Jung ◽

I.H. Park ◽

...

Keyword(s):

Breast Cancer ◽

Gnrh Agonist ◽

Hormone Receptor ◽

Patient Reported Outcomes ◽

Metastatic Breast ◽

Premenopausal Women ◽

Patient Reported